2 completed, 1 recruiting, 1 terminated. 4 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Completed 2, Recruiting 1, Terminated 1 |
| Phase 2 | 4 | Completed 2, Recruiting 1, Terminated 1 |
Follow Nose Neoplasms: new trials by email Literature Review of Nose Neoplasms trials Research Report on Nose Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer SX-682, DTX - Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 120 | 2026-11-18 | 2026-11-13 |
| Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC) Tabelecleucel, Pembrolizumab - Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms | Phase 1 / Phase 2 | Terminated | Atara Biotherapeutics | 12 | 2019-02-19 | 2024-11-14 |
| Phase 1b Food Based Modulation of Biomarkers in Human Tissues at High-Risk for Oral Cancer. placebo, laboratory biomarker analysis, questionnaire administration - Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Salivary Gland Squamous Cell Carcinoma | Phase 1 / Phase 2 | Completed | Ohio State University Comprehensive Cancer Center | 70 | 2007-09-04 | 2020-02-20 |
| Erlotinib, Celecoxib and Reirradiation for Recurrent Head and Neck Cancer erlotinib + celecoxib - Cancer of the Pharynx, Cancer of the Larynx | Phase 1 / Phase 2 | Completed | Johnny Kao | 15 | 2007-02-01 | 2017-04-10 |
Head and Neck Neoplasms (3) · Laryngeal Neoplasms (3) · Paranasal Sinus Neoplasms (3) · Carcinoma (2) · Hypopharyngeal Neoplasms (2) · Nasopharyngeal Carcinoma (2) · Nasopharyngeal Neoplasms (2) · Pharyngeal Neoplasms (2) · Salivary Gland Neoplasms (2) · Squamous Cell Carcinoma of Head and Neck (2) · Carcinoma, Adenoid Cystic (1) · Epstein-Barr Virus Infections (1) · Mouth Neoplasms (1) · Nasopharyngeal Diseases (1) · Neoplasms (1)
Nose Diseases (4) · Respiratory Tract Diseases (4) · Respiratory Tract Neoplasms (4) · Laryngeal Diseases (3) · Neoplasms (3) · Neoplasms by Site (3) · Otorhinolaryngologic Diseases (3) · Otorhinolaryngologic Neoplasms (3) · Paranasal Sinus Diseases (3) · Pharyngeal Diseases (3) · Stomatognathic Diseases (3) · Carcinoma, Squamous Cell (2) · Mouth Diseases (2) · Nasopharyngeal Diseases (2)
Celecoxib (1) · Chemoprevention (1) · Erlotinib Hydrochloride (1) · pembrolizumab (1)
Atara Biotherapeutics (1) · Johnny Kao (1) · National Cancer Institute (NCI) (1) · Ohio State University Comprehensive Cancer Center (1)
United States (4)
Aditi Mehta, DO (1) · Amit Agrawal (1) · Charalampos Floudas, M.D. (1) · Johnny Kao, M.D. (1)